Islatravir 60 mg oral qm showed 64.3% adverse event rate compared to 77.1% in comparator
Trial Shows Islatravir Shows Tolerable Safety Profile for HIV Prevention
This Phase 3 randomized trial evaluated islatravir 60 mg oral qm in 494 cisgender men and transgender women at increased risk of HIV-1 expos…
A Phase 3 trial of islatravir for HIV prevention showed the medication was generally well tolerated with fewer reported side effects than th…
Bictegravir-lenacapavir maintains viral suppression with 0.3% difference compared to bictegravir-emtricitabine-tenofovir alafenamide
Trial shows new daily pill option for people with HIV
This Phase 3 randomized controlled trial of 574 virologically suppressed people with HIV-1 found that switching to a bictegravir-lenacapavir…
A new once-daily pill combination shows similar success in keeping the virus under control compared to current standard treatments.
Bictegravir/emtricitabine/tenofovir alafenamide shows favorable lipid and renal changes versus other regimens in treatment-experienced HIV-1 patients
New review shows a specific HIV drug combo may improve cholesterol and kidney health
This systematic literature review and network meta-analysis evaluates bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) against othe…
A large review found that a specific HIV drug combination improved cholesterol and kidney function compared to other common treatments for e…
F/TAF PrEP shows similar HIV incidence to F/TDF in cisgender women but noninferiority not proven
PrEP pill F/TAF shows similar HIV prevention as F/TDF in women
This RCT in 1380 predominantly cisgender women in East and South Africa compared daily oral F/TAF vs F/TDF for HIV PrEP over 6 months. HIV i…
A study in African women found that a newer PrEP pill (F/TAF) prevented HIV at similar rates to the standard pill (F/TDF), but the study was…
Integrase inhibitor regimen showed non-inferiority and fewer adverse events versus boosted protease inhibitor in advanced HIV
Integrase Inhibitors Show Lower Event Rates Than Boosted Protease Inhibitors in Advanced HIV
This trial compared an integrase inhibitor regimen with a boosted protease inhibitor regimen in therapy-naive adults with advanced HIV disea…
A trial of 447 therapy-naive adults with advanced HIV found fewer drug-related side effects with an integrase inhibitor regimen compared to …
Switching from EFV/TDF/3TC to B/F/TAF or DTG/3TC in virologically suppressed PLWH shows no significant between-group metabolic differences over 24 months
Switching HIV drugs showed similar metabolic changes over two years in this real-world study
This retrospective real-world study evaluated 326 virologically suppressed persons with HIV (PLWH) switching from efavirenz/tenofovir disopr…
Switching HIV drugs caused similar weight gain and metabolic shifts over two years, meaning lifestyle factors matter more than the specific …
Cochrane review: injectable lenacapavir cuts HIV infections versus oral PrEP at 52 weeks
One Shot Saves You From HIV For Six Months
This Cochrane systematic review and meta-analysis of two randomised controlled trials (8660 participants) compared six-monthly subcutaneous …
A single shot under the skin protects against HIV for six months, solving the daily pill problem for millions at risk.
Phase 3 trial compares switch to doravirine/islatravir versus continuing bictegravir/FTC/TAF in HIV-1
Phase 3 trial compares two HIV drug regimens for people already virologically suppressed
A phase 3 randomized controlled trial enrolled 643 virologically suppressed adults with HIV-1 to compare switching to doravirine/islatravir …
People with HIV already on effective treatment can safely switch to a new two-drug pill without losing virus control, according to a complet…